The pharmaceutical industry faces an escalating crisis of escalating costs, protracted timelines, and persistently high failure rates in bringing new…
Read More
From List Price to Net Price: How Finance Leaders Decode Real Drug Costs
In the intricate landscape of the healthcare industry, public discourse and policy debates surrounding drug pricing frequently anchor on the…
Read More
Terray says TerraBind delivers 26x faster inference than Boltz-2 by skipping diffusion-based coordinate generation
In a significant development for AI-driven drug discovery, Terray Therapeutics, a Los Angeles-area startup, has introduced TerraBind, a novel potency…
Read More
How digital tools and AI are accelerating drug discovery
The pharmaceutical industry faces an unprecedented challenge: the relentless rise in drug development costs and timelines, often referred to as…
Read More
FDA refuses to review Moderna’s mRNA flu vaccine
Moderna, a leading biotechnology company known for its pioneering work in mRNA technology, has been dealt a significant setback by…
Read More
SLAS 2026: Orchestration platforms, API-first instruments and the rise of semiautonomous labs
The annual SLAS International Conference and Exhibition, held in Boston from February 7-11, 2026, served as a pivotal moment for…
Read More
Novo Nordisk Sues Hims for GLP-1 Patent Infringement
In a significant escalation of the ongoing battle over the burgeoning GLP-1 weight-loss drug market, pharmaceutical giant Novo Nordisk has…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
The landscape of mental health treatment witnessed a significant development on February 17, 2026, as Compass Pathways, a leading mental…
Read More
FDA reverses course, agrees to review Moderna’s mRNA flu vaccine
The U.S. Food and Drug Administration (FDA) has officially reversed its earlier stance, agreeing to review Moderna’s messenger RNA (mRNA)…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
